Manufacturer record
YL Pharma: regulatory record
Last checked 3 November 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
9 batches manufactured by YL Pharma (Himachal Pradesh) were declared Not of Standard Quality between September 2025 and February 2026. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Most recent flagged batch: YLT25023, Paracetamol, Phenylephrine Hydrochloride Diphenhydramine, Hydrocloride & Caffeine Tablets (exp May 2027). DTL Jaipur (state lab) found it not of standard quality: The sample does not conform to the claim with respect to in Assay of Phenylephrine Hydrochloride & Caffeine (Anhydrous) (NIL). Listed in the February 2026 alert.
Records by type
9 records linked to YL Pharma in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Paracetamol, Phenylephrine Hydrochloride Diphenhydramine, Hydrocloride & Caffeine Tablets | Batch YLT25023Mfg Jun 2025 · Exp May 2027 | The sample does not conform to the claim with respect to in Assay of Phenylephrine Hydrochloride & Caffeine (Anhydrous) (NIL).Assay | DTL JaipurState lab | Feb 2026 |
| Levocetirizine Dihydrochloride & Montelukast Sodium Tablets IP | Batch LT-25029Mfg Sep 2025 · Exp Aug 2027 | The sample does not HP conform to the IP with respect to Assay.Assay | DTL, JaipurState lab | Dec 2025 |
| Levocetirizine Dihydrochloride Tablets | Batch YLT25023Mfg Mar 2025 · Exp Feb 2027 | The sample does not conform to the IP with respect to AssayAssay | DTL, JaipurState lab | Dec 2025 |
| Diclofenac Potassium & Paracetamol Tablets (MUSCARE-P TAB.) | Batch YLT25027Mfg Jul 2025 · Exp Jun 2027 | Diclofeanc Potassium Assay 83.54% & Assay Of Paracetamol 79.83%Assay | DTL BADDIState lab | Dec 2025 |
| Ofloxacin Tab IP 200mg | Batch YLT25025Mfg Jun 2025 · Exp May 2027 | The Sample Does not conform to the IP with respect to AssayAssay | DTL, JaipurState lab | Nov 2025 |
| Levocetirizine Dihydrochloride & Montelukast Sodium Tablets | Batch YLT25029Mfg Sep 2025 · Exp Aug 2027 | The Sample Does not conform to the IP with respect to AssayAssay | DTL, JaipurState lab | Nov 2025 |
| Levocetirizine DiHydrochloride Tablets | Batch YLT25028Mfg Jul 2025 · Exp Jun 2027 | The Sample Does not conform to the IP with respect to AssayAssay | DTL, JaipurState lab | Nov 2025 |
| Levocetirizine Dihydrochloride Tab (Wineet-L) | Batch YLT25023Mfg Mar 2025 · Exp Feb 2027 | The sample does not conform to the IP as it does not contain Levocetirizine DihydrochlorideOther | DTL, JaipurState lab | Oct 2025 |
| Paracetamol, Phenylephrine Hcl, Caffeine & Diphenhydramine Hcl Tablets | Batch YLT25006Mfg Jan 2025 · Exp Dec 2026 | Identification & AssayAssay | DTL ,Baddi, HPState lab | Sep 2025 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.